Ekimas Corp (ASNB) SEC Filing 10-Q Quarterly Report for the period ending Wednesday, June 30, 2021

Advansource Biomaterials Corp

CIK: 1499961 Ticker: ASNB
Cover - shares
3 Months Ended
Jun. 30, 2021
Sep. 23, 2021
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateJun. 30, 2021 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Current Fiscal Year End Date--03-31 
Entity File Number0-28034 
Entity Registrant NameEKIMASCORPORATION 
Entity Central Index Key0001011060 
Entity Tax Identification Number04-3186647 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One95 Washington Street 
Entity Address, Address Line Two#154 
Entity Address, City or TownCanton 
Entity Address, State or ProvinceMA 
Entity Address, Postal Zip Code02021 
City Area Code978 
Local Phone Number344-2124 
Title of 12(g) SecurityCommon Stock, $0.001 par value per share 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Business Flagtrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companytrue 
Entity Common Stock, Shares Outstanding 28,262,371

View differences made from one quarter to another to evaluate Advansource Biomaterials Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Advansource Biomaterials Corp.


Assess how Advansource Biomaterials Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Advansource Biomaterials Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Advansource Biomaterials Corp provided additional information to their SEC Filing as exhibits

Ticker: ASNB
CIK: 1011060
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-21-023473
Submitted to the SEC: Thu Sep 23 2021 1:50:35 PM EST
Accepted by the SEC: Thu Sep 23 2021
Period: Wednesday, June 30, 2021
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: